The idea of mesenchymal cells or MSCs for MS has been around for a long time. However, there haven’t been that many strong clinical trials testing it. There’s a new paper out that reports one of the stronger MSC-related trials for MS in terms of design. In this case, they didn’t use just MSCs but […]
Mostly discouraging trial of MSC-NPs or purported neural cells from MSCs for MS Read More »
For about as long as I’ve been writing The Niche, people have been asking about stem cells for MS. There’s a huge need for new therapies. While a chemo-based approach with autologous hematopoietic stem cell transplantation (HSCT) looks to work for certain cases of multiple sclerosis (although not yet approved in the US), other cell
Weekly reads: stem cells for MS, good news x2, extending dog years, Neuralink updates Read More »
There has been a steady stream of encouraging data on stem cells for MS. Particularly for certain kinds of MS. A new study adds to this upbeat direction. Good news on stem cells for MS Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study, Journal of Neurology, Neurosurgery,
Weekly reads: stem cells for MS, Kimera Labs IND, FDA lawsuit Read More »
About 1 million people are living with multiple sclerosis in the U.S. alone with millions of other cases around the world so a huge effort has gone into trying to find new approaches to the disease including stem cells for MS. We’ll start our weekly recommended reads by talking about a new paper on MS
Stem cells for MS & other weekly reads: CRISPR, COVID & a bat cave, Huntington’s Read More »
I’ve ended up learning a lot about multiple sclerosis (MS) while writing The Niche for the past twelve plus years, but I’ve never seen anything like the new research linking EBV and MS. EBV stands for Epstein Barr Virus. The reason I’ve learned much more about MS while writing here is that there has been
Stronger link between EBV and MS brings concrete clinical hope Read More »
I’m continuing my stem cell patient Q&A series and today’s Q&A#2 post is focused on whether autoimmune patients generally or specifically those who have received chemo and hematopoietic stem cell transplants (HSCT) are at higher risk from COVID-19? Multiple patients have asked me this. It’s a great question and obviously urgent right now during the
“HSCT Chicago Clinic Closing!” is the startling header in all caps on a patient-run Facebook page about a stem cell therapy clinical trial program at Northwestern University. What’s going on? Unfortunately, the promising field of hematopoietic stem cell transplantation (HSCT) for multiple sclerosis (MS) and other autoimmune diseases seems to have suffered an unexpected setback
Northwestern abruptly ending Burt HSCT autoimmune trials Read More »
Stem cells for MS? How promising is that? A new paper gives stronger reason for hope, but unfortunately this story is more complex than it seems on first glance. New Paper The idea of using a stem cell-related approach to treat multiple sclerosis (MS) has been around for a long time holding major promise, but
Upbeat Burt team pub on stem cells for MS comes with uneasy back story Read More »
Multiple sclerosis (MS) can be an extremely debilitating disease that ultimately is fatal in some patients and reduces life expectancy and quality overall substantially. An MS patient named Caroline Wyatt, who works at the BBC, had the courage to open up in full detail on the BBC about having MS, her experience getting an experimental
Patient’s Powerful Story on Multiple sclerosis and Getting Experimental Stem Cells Read More »
By Hamideh Emrani (@HamidehEmrani) This year, Dr. Harold Atkins was honored with the Till & McCulloch Award. He and Dr. Mark Freedman led a clinical trial that used stem cells to reset the immune system as a treatment strategy for Multiple Sclerosis (MS) and a few other neurodegenerative diseases, such as stiff person syndrome. You can